2017 Press Releases

Webcast ImageWebcast
REGENXBIO at the Annual LEERINK Partners Global Healthcare Conference (Replay)
02/15/17 at 10:30 a.m. ET
REGENXBIO at the Annual LEERINK Partners Global Healthcare Conference
Wednesday, February 15, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
02/14/17REGENXBIO Announces IND Active for Phase I Trial of RGX-314 to Treat Wet Age-Related Macular Degeneration
Six leading U.S. retinal surgery centers expected to participate as enrollment sites in the trial Anticipate beginning trial enrollment by mid-2017; interim trial update expected by the end of 2017 ROCKVILLE, Md., Feb. 14, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announce... 
Printer Friendly Version
02/09/17REGENXBIO to Present at the 6th Annual LEERINK Partners Global Healthcare Conference
ROCKVILLE, Md., Feb. 09, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the 6th Annual LEERINK Partners Global Healthcare Conference on Wednesday, February 15, 2017 at the Lotte New York Palace in New York City. A live webcast of REGENXBIO’s pre... 
Printer Friendly Version
02/02/17REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
ROCKVILLE, Md., Feb. 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day. The conference will take place on Tuesday, February 14, 2017 at the JW Marriott Essex House New York in New York, NY. REG... 
Printer Friendly Version
01/06/17REGENXBIO Provides Year-End 2016 Corporate Update
Filed IND for RGX-314 Phase I clinical trial for wet AMD Announced initiation of protocol changes for RGX-501 Phase I/II clinical trial for HoFH; patient enrollment is now projected to begin first half 2017 Anticipate enrolling patients in clinical trials for three lead programs and filing an additional IND in 2017 Enhanced advanced manufacturing and analytics infrastructure and capabilities Ended 2016 with greater than $155 million in cash, cash equivalents and marketable securities... 
Printer Friendly Version